Epcoritamab for lymphoma that returns after an organ transplant
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have post-transplant lymphoproliferative disorder (a type of lymphoma that can happen after an organ transplant) that did not respond to a treatment with rituximab or rituximab plus chemotherapy.
- You must have had a solid organ transplant (such as kidney, liver, heart, lung, pancreas, or intestine).
- You must have a tumor that is at least 1.5 cm on a scan or cancer cells in your bone marrow.
- Your overall health should be reasonably good (able to care for yourself, even if you may need some help).
- You must have adequate kidney, liver, and blood cell function as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Hear when a new Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.